Tennis Elbow (Lateral Epicondylitis)
Conditions
Interventions
Trade Name: Depo-Medrone
Product Name: Depo-Medrone
Product Code: Depo-Medrone
Pharmaceutical Form: Injection*
Sponsors
Whipps Cross University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients deemed by their general practitioners to have a diagnosis of tennis elbow and referred to the outpatient department for further management will be assessed for their suitability for inclusion in the study. Criteria for inclusion in the study would be patients with symptoms of tennis elbow who had not had treatment for this complaint in the preceding 3 months. Symptoms include pain reproduced on palpation of the common extensor origin, pain reproduced on resisted extension of the wrist with the elbow extended. All participants must be age over 18 years. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Criteria Resulting in Exclusion from the Study: 1. Trauma to the affected elbow in the preceding 6 weeks 2. Patients with a past history of elbow instability 3. Previous elbow surgery 4. Bilateral symptoms 5. Any other pathology involving the affected upper limb 6. Coexisting cervical spine pathology 7. Physiotherapy or steroid injection for the presenting condition within the previous 3 months 8. Patients already on oral/systemic steroids 9. Patients with contraindications to injection therapy: (i) Patients with bleeding diatheses or on anticoagulant therapy (ii) Local or systemic infection (iii) Past history of hypersensitivity to local anaesthetics (iv) Poorly controlled diabetics and other immunosuppressed individuals (v) Pregnant or breast feeding patients (vi) Uncooperative patients with an underlying psychiatric diagnosis (vii) Prosthetic elbow joint
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To establish that an intramuscular steroid injection is as effective in relieving pain and improving function at 6 weeks as an intralesional steroid injection. To establish that an intramuscular injection is less painful at the point of delivery than an intralesional steroid injection. ;Secondary Objective: ;Primary end point(s): Primary outcome will be 1. Pain Severity and Functional Disability as assessed by a Patient Rated Tennis Elbow Evaluation Questionnaire : 1- Before the injection, 2- 6 weeks later at Follow up, 2. Pain severity at the site of the injection as assessed by a 10 point Likert scale: 1- Immediately after the injection 2- 24 hours later, 3- 48 hours later | — |
Countries
United Kingdom
Outcome results
None listed